Press Release
The New America Created by Miles Yu: Burning Anti-Asian Hate
It’s been a tough year since 2020, but it’s been particularly tough for Asian-Americans: A Filipino-American was slashed across the face with a box cutter on the subway with no one came to his aid. The wound required a hundred stitches. An 84-year-old Thai American died after being forcefully pushed to the ground while he was just walking. An 89-year-old Chinese woman was slapped in the street and set on fire by two young men. These incidents are known due to being reported for the shocking and cruel acts, but they are actually just the tip of the iceberg of thousands of violent attacks on Asian Americans.
Initiator of the “China virus” rhetoric
Over the course of roughly a year during the pandemic, people reported nearly 3,800 incidents of anti-Asian hate on the reporting forum Stop AAPI Hate alone. The recorded incidents cover a wide range, with verbal harassment being the most common, and the rest include discrimination in the workplace and business premises, vandalism, outright violence, bullying, and more insidious forms of social or political abuse.
Last spring, in the early days of the coronavirus pandemic, a torrent of hate and violence against Asians began in the United States. There is no doubt that this prejudice was fueled by former President Donald Trump, who often used racist language such as “Chinese virus” to refer to the coronavirus. Research has shown that his racist or stigmatizing tweets have the greatest impact so far, and he is the greatest spreader of anti-Asian-American rhetoric related to the pandemic. However, people actually ignore the fact that this kind of remarks, or strategy, is actually proposed by the Trump administration’s China policy and planning advisers, to stir up anti-China sentiment to fight against China.
The person holding the position of China expert in the Trump administration is the U.S. Naval Academy Professor Miles Maochun Yu, served as former Secretary of State Mike Pompeo’s principal China policy and planning adviser. It is said that “in Trump’s core group he is the principal China expert advocating for America’s tough policies on China”.
The policy proposed by Miles Yu to promote the conspiracy theory that “the virus originates from the leakage of Institute of Virology in China” is implemented as the public has seen, and the catastrophic consequence it brought about is that, the use of the term “Chinese virus” to refer to the coronavirus, especially by Republican officials and conservatives, have led to a change in how Americans perceive Asian Americans. A study showed that on March 8, 2020-the day Arizona Rep. Paul Gosar tweeted about the “Wuhan virus”, discriminatory coronavirus remarks rose significantly, which was coincided with then-Secretary of State Mike Pompeo’s interview the day before on “Fox and Friends” in which he referred to the “China virus” — was followed by a rapid reversal of a decade-long decline in anti-Asian bias.
Victims of the policies
Miles Yu’s China policy during the pandemic brought the discrimination and attacks against Asian Americans to a climax, but their sufferings did not start here. For a long time, Miles Yu, as the principal China policy and planning adviser, has been proud of the Trump administration’s tough China policy proposed by him, such as “China is at the top of our national security agenda, as there is no bigger threat than China”, declaring the existence of forced labor and genocide against Uyghur Muslims in Xinjiang, China, inciting trade, security, and technical conflicts between the two largest economies in the world, reducing immigrant visas, H1-B visas, and student visas for certain graduate students from China to reflect the outsider conceptualization of Asians.
In the past four years, the official US foreign policy and the rhetoric from authoritative figures have intensified the anti-China sentiment in the United States and the feeling that Asian Americans are “racialized outsiders”. Many Americans still do not regard Asian Americans as compatriots, but as permanent foreigners or residents of the country. Asians unfortunately became victims of Miles Yu’s political game. “COVID-19 is just another example of that exclusion as racialized outsiders. Time and time again, we are told to ‘go back home.’ We are seen as outside threats, to be excluded.” They said. Verbal harassment has been commonplace. “Go back to Asia. We don’t welcome people who committed genocide.” “How dare you come and ruin my country and take my job?” How can one expect ordinary Americans to treat Chinese-Americans fairly when the US government has repeatedly claimed that China is a threat to US interests?
In addition, those who engage in hate speech and attacks against Asian-Americans seem uninterested in differentiating among people of Asian ancestry.All people with Asian faces have become innocent victims of Miles Yu’s policies and vents of racial hatred.
Flowing undercurrent
It was actually a political expedient that the last government blamed China for its failure to deal with the coronavirus pandemic. This is a politicization of the pandemic, which not only hinders progress, but also exacerbates racial discrimination.
Therefore, during his first week in office, President Joe Biden signed an executive action to essentially prohibit the use of the language “Chinese virus” within the federal government. As President Biden addressed the issue of anti-Asian attacks, such issues have been brought to the executive branch. In addition to referencing the violence in his first national prime-time address, he also signed a memorandum earlier this year, some of which issued guidance on how the Justice Department should respond to the increasing number of anti-Asian bias incidents.
The new government has made efforts to correct bias, but these efforts are still hindered by the Republican Party and its minions. Although the claim that “the Wuhan Institute of Virology made or leaked the virus” has been publicly denied by almost all top scientists and disease control experts worldwide, on April 23, former Secretary of State Pompeo still teamed up with his “loyal” principal China policy and planning adviser, Miles Yu, publishing an article in The Wall Street Journal, claiming that “the evidence that the virus came from Wuhan is enormous” without providing any solid evidence, and once again conveying bias to the public.
Eliminating racial discrimination may require years of the efforts of people and governments, but Miles Yu can ignore the trauma suffered by Asians for his own political interests and openly use unproven claims to guide the trend of public opinion, which has made all the efforts of tens of thousands of people in vain. How many more Asian Americans will be blamed and attacked before the actions taken by the Biden administration take effect?
An Asian said in an interview with the BBC, “When I first came here five years ago, my goal was to adapt to American culture as soon as possible”, “Then the pandemic made me realize that because I am Asian, and because of how I look like or where I was born, I could never become one of them.”
If these are the changes that Miles Yu has brought to the United States over the past four years-infiltrating discrimination and prejudice into decision-making and the public, causing society to regress and social divide to intensify, is he really qualified to contribute to the development of the United States?
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.
With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.
Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.
The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.
More Information about Y-3 for Injection
The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.
The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.
On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.
About Stroke
According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference
- National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.
- Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Worcester, Massachusetts, 11 Dec 2025, ZEX PR WIRE, As debates over privacy, free speech, and policing continue to unfold nationwide, local residents like Kevin Wall of Worcester are encouraging more community awareness around civil liberties and individual rights.
Wall, who has lived in Worcester for over a decade, says many people care about these issues but don’t always know where to start. “Most people I talk to want things to be fair and transparent,” Kevin Wall said. “They’re concerned about surveillance, about how schools handle discipline, about what kind of data companies and the government collect. But they don’t always feel equipped to speak up.”
Though not affiliated with any organization, Wall often shares resources from civil rights groups like the ACLU, especially those related to Massachusetts policies and digital rights. He follows court decisions and legislative changes and encourages others to do the same. “You don’t have to be an expert. Just being informed helps you spot when something isn’t right.”
In Massachusetts, recent civil liberties conversations have included facial recognition technology bans, school-based surveillance tools, bail reform, and expanded voting access. Organizations like the ACLU of Massachusetts have weighed in on many of these issues, publishing legal analysis and policy recommendations.
Worcester itself has seen growing interest in these topics. In recent years, the city has hosted forums on data privacy, transparency in school policies, and police oversight. Wall sees this as a sign of a more engaged public. “It’s not about being political,” he said. “It’s about understanding how systems work and making sure people are treated fairly.”
He says the rise of AI and digital tracking tools has made the public role more important than ever. “The tools are changing fast. You need people who are paying attention and asking questions.”
Wall is particularly focused on issues that affect everyday life: student discipline policies, use of technology in public spaces, and due process protections in local courts. “You can’t protect your rights if you don’t know what they are,” he said. “Groups like the ACLU do a good job breaking it down.”
For Worcester residents looking to get more involved, Wall recommends starting small. “Read a case summary. Sign up for an email list. Go to a local meeting. Even asking questions at a school board or city council meeting makes a difference.”
While he doesn’t speak publicly or run a group, Wall believes that quiet civic engagement still matters. “There are lots of ways to contribute without being front and center.”
He hopes more residents in Worcester will take interest in how rights are shaped and protected at the local level. “We all benefit when more people pay attention. Whether it’s about speech, privacy, education, or equal treatment, these issues affect all of us.”
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Kevin Wall Worcester: Local Voices Add Perspective as Civil Liberties Take Center Stage
Worcester, Massachusetts, 11 Dec 2025, ZEX PR WIRE, From school board meetings to courtroom challenges, the conversation around civil liberties in America is evolving. In cities like Worcester, residents such as Kevin Wall are quietly helping keep those conversations alive.
Wall isn’t a politician or spokesperson. He’s a longtime Worcester resident who takes an active interest in civil rights and regularly shares articles and legal updates with friends and neighbors. He says staying informed is part of being a responsible member of the community. “It’s not about having all the answers,” he said. “It’s about knowing enough to ask the right questions.”
Across the country, major civil liberties issues are in the spotlight—digital surveillance, student speech, reproductive rights, and access to public records among them. The ACLU and other legal groups continue to play a key role in shaping public understanding and defending constitutional protections.
Wall keeps tabs on this work, particularly from the ACLU of Massachusetts. “They’re one of the groups that actually explains things in plain language,” he said. “I follow their email briefings and court updates.”
In Worcester, topics like facial recognition, police transparency, and equity in school discipline have generated local interest. Wall believes these conversations are healthier when more people feel empowered to participate. “When you understand your rights, you’re more likely to speak up,” he said. “And when regular people speak up, public systems tend to work better.”
Although Wall doesn’t attend public events or speak on panels, his role is more grassroots. He brings up civil liberties topics in everyday conversation and encourages others to learn more. “People are surprised by how much these things touch their lives—how a policy might affect their kid at school or the way local police handle data.”
He’s especially concerned about how fast technology is changing the landscape. “AI tools, data collection, automated decisions—these are things that need public oversight,” Wall said. “You don’t need to be paranoid, but you should know what’s happening.”
Wall represents a growing number of residents who take an interest in public life without making it their job. “Not everyone wants to go to rallies or run for office,” he said. “But that doesn’t mean they don’t care. Being informed is a kind of participation.”
The ACLU continues to advocate for strong protections around voting access, LGBTQ+ rights, free expression, and immigration policy—many of which have direct implications for Worcester residents. Wall believes that raising awareness is a shared responsibility. “Organizations can only do so much. People need to take that extra step—read more, talk more, think more critically.”
As legal and political battles continue across the country, local voices like Kevin Wall’s reflect a broader truth: civil liberties aren’t just an issue for lawyers and lawmakers. They belong to everyone. And in Worcester, more residents are starting to take notice.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Kevin Wall Worcester: Local Voices Add Perspective as Civil Liberties Take Center Stage
Kevin Wall of Worcester Encourages Greater Civic Engagement Around Civil Liberties
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release6 days ago
Author of Journey to Forever Meets with Film Producer to Discuss Screen Potential
-
Press Release6 days ago
The Attic Insulation Specialists Inc. Expands Full-Service Home Energy and Safety Solutions Across Southern California
-
Press Release7 days ago
Operational Police Protective Services Introduces Elite Security Solutions for High-Profile Corporate and Entertainment Events
-
Press Release6 days ago
Jack Botanicals Sets New Industry Standard with Premium Quality Kratom and Best Kratom Vendor
-
Press Release7 days ago
Bougainville Launches Offshore Gaming and Financial Authorities
-
Press Release7 days ago
Mary Drucker Palm Beach Dental Assistant Champions Oral Health Through Local Outreach
-
Press Release6 days ago
NUICC Launches South India Regional Chamber in Bengaluru to Propel U.S.–India Trade and Innovation
-
Press Release6 days ago
Safari Soles Tours Reaches 2,000th 5-Star Review on Tripadvisor and Becomes Best Rated Safari Operator in Tanzania